<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effects of NSP-513, (R)-4,5-dihydro-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-6-[4-(2-<z:chebi fb="1" ids="26308">propyl</z:chebi>-3-oxo-1-cyclohexenyl)amino] <z:chebi fb="1" ids="30396">phenyl</z:chebi>-3(2H)-<z:chebi fb="0" ids="26414">pyridazinone</z:chebi>, on phosphodiesterase (PDE) isozyme activities, in vitro platelet aggregation and in vivo <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="1" pm="."><plain>NSP-513 selectively inhibited human platelet PDE 3 isozyme with an IC50 value of 0.039 microM </plain></SENT>
<SENT sid="2" pm="."><plain>In an in vitro human platelet aggregation assay, the IC50 values (microM) of NSP-513 for platelet aggregation induced by collagen, U-46619, <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>, <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>), <z:chebi fb="2" ids="28918">epinephrine</z:chebi> and thrombin were 0.31, 0.25, 0.082, 0.66, 0.23 and 0.73, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In a mouse pulmonary <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> model, orally administered NSP-513 showed in vivo antithrombotic effects that were 320 to 470 times more potent than those of cilostazol </plain></SENT>
<SENT sid="4" pm="."><plain>In a rat carotid <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> model, intraduodenally administered NSP-513 (0.1 mg/kg), cilostazol (30 mg/kg) and aspirin (30 mg/kg) reduced <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation by 75%, 66% and 48%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>However, intravenously administered <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (10 mg/kg) did not significantly prevent <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation </plain></SENT>
<SENT sid="6" pm="."><plain>These results demonstrate that NSP-513 has the potential to prevent not only in vitro platelet aggregation but also in vivo <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and indicate that the highly selective PDE 3 inhibitory effect of NSP-513 may make this compound useful for assessing the physiological role of PDE 3 </plain></SENT>
</text></document>